EPS for Myriad Genetics, Inc. (MYGN) Expected At $0.27; Glenview Capital Management Trimmed Anthem (ANTM) Position

April 21, 2018 - By Henry Gaston

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

Glenview Capital Management Llc decreased Anthem Inc (ANTM) stake by 19.59% reported in 2017Q4 SEC filing. Glenview Capital Management Llc sold 745,018 shares as Anthem Inc (ANTM)’s stock declined 2.73%. The Glenview Capital Management Llc holds 3.06M shares with $687.97 million value, down from 3.80 million last quarter. Anthem Inc now has $57.84 billion valuation. The stock decreased 0.70% or $1.6 during the last trading session, reaching $226.07. About 1.13 million shares traded. Anthem, Inc. (NYSE:ANTM) has risen 35.30% since April 21, 2017 and is uptrending. It has outperformed by 23.75% the S&P500.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.27 EPS on May, 1.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.27 EPS. MYGN’s profit would be $18.86 million giving it 26.76 P/E if the $0.27 EPS is correct. After having $0.31 EPS previously, Myriad Genetics, Inc.’s analysts see -12.90% EPS growth. The stock decreased 0.48% or $0.14 during the last trading session, reaching $28.9. About 277,808 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has risen 52.68% since April 21, 2017 and is uptrending. It has outperformed by 41.13% the S&P500.

Analysts await Anthem, Inc. (NYSE:ANTM) to report earnings on April, 25 before the open. They expect $4.93 earnings per share, up 5.34% or $0.25 from last year’s $4.68 per share. ANTM’s profit will be $1.26B for 11.46 P/E if the $4.93 EPS becomes a reality. After $1.29 actual earnings per share reported by Anthem, Inc. for the previous quarter, Wall Street now forecasts 282.17% EPS growth.

Glenview Capital Management Llc increased Fedex Corp (NYSE:FDX) stake by 401,606 shares to 529,127 valued at $132.04 million in 2017Q4. It also upped Universal Hlth Svcs Inc (NYSE:UHS) stake by 1.83M shares and now owns 4.13 million shares. Vereit Inc was raised too.

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 16 have Buy rating, 0 Sell and 8 Hold. Therefore 67% are positive. Anthem Inc had 75 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, October 2 by Citigroup. The firm has “Outperform” rating by Leerink Swann given on Monday, April 4. The stock of Anthem, Inc. (NYSE:ANTM) has “Mkt Perform” rating given on Thursday, October 29 by FBR Capital. The firm earned “Buy” rating on Friday, November 17 by Bank of America. Cleveland initiated Anthem, Inc. (NYSE:ANTM) on Friday, April 8 with “Buy” rating. Stifel Nicolaus downgraded Anthem, Inc. (NYSE:ANTM) on Wednesday, January 4 to “Hold” rating. The stock of Anthem, Inc. (NYSE:ANTM) earned “Neutral” rating by JP Morgan on Monday, October 17. The firm has “Outperform” rating given on Tuesday, November 15 by Wells Fargo. The company was downgraded on Tuesday, May 24 by Sterne Agee CRT. The firm has “Outperform” rating given on Thursday, June 16 by Bernstein.

Investors sentiment increased to 1.37 in 2017 Q4. Its up 0.51, from 0.86 in 2017Q3. It increased, as 19 investors sold Myriad Genetics, Inc. shares while 67 reduced holdings. 46 funds opened positions while 72 raised stakes. 71.43 million shares or 0.51% less from 71.79 million shares in 2017Q3 were reported. Shell Asset Management owns 0.01% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 19,554 shares. Clearbridge Investments Ltd Liability Company invested in 0% or 1,437 shares. Acadian Asset Management Limited Liability Corp has invested 0.33% in Myriad Genetics, Inc. (NASDAQ:MYGN). Gotham Asset Management Limited stated it has 0.07% in Myriad Genetics, Inc. (NASDAQ:MYGN). White Pine Ltd Liability Company holds 10,025 shares or 0.13% of its portfolio. Moreover, Camber Cap Mgmt Limited has 2.52% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Teacher Retirement Systems Of Texas invested 0.01% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Atlantic Trust Llc stated it has 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Axa has 0.01% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Morgan Stanley holds 415,022 shares or 0% of its portfolio. Macquarie Gru Limited invested 0.01% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Renaissance Tech Limited Liability Company accumulated 0.01% or 217,279 shares. Nordea Mngmt Ab accumulated 0.01% or 71,278 shares. Oberweis Asset has 0.08% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,584 shares.

Among 20 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 4 Sell and 12 Hold. Therefore 20% are positive. Myriad Genetics had 59 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Bank of America given on Friday, July 29. The company was maintained on Tuesday, September 15 by Piper Jaffray. The stock has “Hold” rating by Jefferies on Thursday, August 11. The stock has “Neutral” rating by Mizuho on Wednesday, November 4. As per Friday, August 18, the company rating was upgraded by Deutsche Bank. Barclays Capital downgraded the stock to “Equal-Weight” rating in Wednesday, August 10 report. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, August 25. The rating was maintained by Cowen & Co on Monday, August 14 with “Hold”. The firm has “Hold” rating by Jefferies given on Monday, June 12. The stock has “Market Perform” rating by Leerink Swann on Wednesday, February 7.

Since December 11, 2017, it had 0 insider purchases, and 7 sales for $5.48 million activity. 6,000 shares were sold by DREISMANN HEINRICH, worth $201,000 on Monday, December 11. MARSH RICHARD M sold $498,764 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) on Friday, January 12. King Gary A. had sold 3,120 shares worth $118,934 on Thursday, January 18. Shares for $248,925 were sold by GILBERT WALTER PHD on Thursday, December 14.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.02 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 15.5 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>